Dementia Diagnostic Criteria

Core Clinical Criteria for All-Cause Dementia

• The American Academy of Neurology recommends that dementia is diagnosed when cognitive or behavioral symptoms interfere with the ability to function at work or usual activities, represent a decline from previous functioning, are not explained by delirium or major psychiatric disorder, and involve impairment in at least two cognitive domains 1, 2
• The diagnosis requires three essential elements: functional impairment, documented decline, and exclusion of other causes, as suggested by the American Academy of Neurology 1, 3, 4
• Functional impairment means cognitive or behavioral symptoms must interfere with ability to function at work or usual activities, according to the American Academy of Neurology 1, 2
• Documented decline means symptoms must represent a decline from previous levels of functioning and performing, as stated by the American Academy of Neurology 1, 3
• Exclusion of other causes means symptoms are not explained by delirium or major psychiatric disorder, as recommended by the American Academy of Neurology 1, 2

Cognitive Domain Assessment

• Cognitive impairment must be detected through both history-taking from the patient and a knowledgeable informant AND objective cognitive assessment, such as bedside mental status examination or neuropsychological testing, as suggested by the American Academy of Neurology 1, 2
• The cognitive or behavioral impairment must involve a minimum of two of the following five domains: memory impairment, executive dysfunction, visuospatial impairment, language dysfunction, and behavioral/personality changes, according to the American Academy of Neurology 1, 2, 4

Diagnostic Assessment Algorithm

• The American Academy of Neurology suggests obtaining detailed information about cognitive concerns from both the patient AND a knowledgeable informant, focusing on onset, progression pattern, and impact on instrumental activities of daily living 2, 5, 6
• Standardized cognitive screening tools, such as the Mini-Mental State Examination (MMSE) and the Montreal Cognitive Assessment (MoCA), should be used, as recommended by the American Academy of Neurology 5, 6

Critical Distinction from Mild Cognitive Impairment

• The differentiation of dementia from MCI rests on whether there is significant interference in the ability to function at work or in usual daily activities, as stated by the American Academy of Neurology 1, 4, 7

Important Nuances

• Memory impairment is NOT always the primary deficit in dementia, and nonamnestic presentations can occur, particularly with onset before age 65, including language-predominant, visuospatial-predominant, or executive dysfunction-predominant presentations, according to the American Academy of Neurology 1, 3, 4

Dementia Classification and Diagnosis

Official Diagnostic Classification

• The American Psychiatric Association uses the term "major neurocognitive disorder" as the formal diagnostic label for dementia, distinguishing it from primary psychiatric disorders 8, 9

Diagnostic Criteria

• Dementia diagnosis requires impairment in at least two of five cognitive domains: memory, executive function, visuospatial abilities, language, or personality/behavior, which is characteristic of neurodegenerative disease rather than primary psychiatric illness 9

The Complex Relationship with Psychiatric Disorders

• The American College of Radiology notes that psychiatric symptoms are extremely common in dementia and can be the presenting feature, but this does not make dementia a psychiatric disorder 8, 10
• More than half of patients who develop dementia have depression or irritability symptoms before cognitive impairment becomes apparent 10
• Specific dementia subtypes can present with prominent psychiatric symptoms that are difficult to differentiate from primary psychiatric disorders 10, 11
• However, patients with behavioral variant frontotemporal dementia most often do not fulfill formal DSM-5 criteria for another mental disorder when rigorously evaluated 11

Practical Clinical Implications

• The American Academy of Neurology recommends that when evaluating suspected dementia, primary psychiatric disorders should be actively excluded through rigorous application of DSM-5 criteria combined with expert clinical judgment 11
• Consultation with a psychiatrist with expertise in frontotemporal dementia is recommended when primary psychiatric disorders are on the differential diagnosis, as this requires specialized diagnostic expertise 11

Evidence‑Based Diagnostic Framework for Major Neurocognitive Disorder (Dementia)

Definition and Core Diagnostic Elements

• Major neurocognitive disorder is diagnosed when cognitive or behavioral symptoms interfere with work or usual activities, represent a decline from prior functioning, are not attributable to delirium or a major psychiatric disorder, and involve impairment in at least two cognitive domains【12】.
• Functional impairment is defined as the need for assistance with complex instrumental activities of daily living (e.g., managing finances or medications)【12】.
• A documented decline must be demonstrable compared with previous levels of functioning【12】.
• The diagnosis requires exclusion of delirium and major psychiatric illness as alternative explanations【12】.

Cognitive Assessment Requirements

• Diagnosis requires information from both the patient and a knowledgeable informant together with an objective cognitive assessment (either bedside mental‑status exam or formal neuropsychological testing)【12】.
• Formal neuropsychological testing is recommended when routine history and bedside examination do not yield a confident diagnosis【12】.
• At least two of the five cognitive domains must be impaired:

Mild Cognitive Impairment (MCI) – Distinguishing Features

• MCI is characterized by a subjective cognitive concern reported by the patient, informant, or clinician【13】.
• Objective testing shows impairment in one or more cognitive domains【13】.
• Independence in functional abilities is preserved, although there may be mild difficulty with complex tasks【13】.
• By definition, individuals with MCI do not meet criteria for dementia【13】.

Etiologic Subtypes with Core Clinical Patterns

Alzheimer Disease (AD)

• Amnestic presentation (most common): prominent difficulty with learning and recalling recent information plus dysfunction in at least one additional domain【13】.
• Non‑amnestic presentations may predominate in language, visuospatial skills, or executive function【13】.
• Onset is insidious, with gradual progression over months to years【13】.

Vascular Dementia

• Characterized by substantial cerebrovascular disease with either:

Biomarker Evidence for Alzheimer Disease Pathophysiology

• Amyloid‑β biomarkers:
• Neurodegeneration biomarkers:
• Interpretation rule: Presence of both amyloid and neurodegeneration biomarkers yields a high likelihood that dementia is due to AD, whereas absence of both makes AD highly unlikely【13】.

Clinical Judgment in Diagnostic Boundaries

• Distinguishing normal cognition, MCI, and dementia often lacks sharp demarcations; clinical judgment is essential for accurate classification【15】.

Evidence‑Based Diagnostic Criteria for Dementia Subtypes

Clinical Phenotype Recognition

• Identifying the dominant clinical phenotype (which cognitive domains are impaired and which are preserved) and then confirming the impression with biomarkers yields the most effective approach to differentiating dementia types. 16
• In Alzheimer’s disease (AD), the typical presentation is amnestic: patients have prominent difficulty learning and recalling recent information (hippocampal‑type memory impairment) together with dysfunction in at least one other cognitive domain. 16
• Non‑amnesic AD variants—such as posterior cortical atrophy and logopenic primary progressive aphasia—are recognised but occur less frequently than the classic amnestic form. 16

Biomarker Requirements for Alzheimer’s Disease

• A definitive AD diagnosis requires both amyloid‑positive and tau‑positive biomarkers; amyloid positivity alone is insufficient because it can be present in other conditions (e.g., Lewy body dementia, vascular cognitive impairment). 16
• When AD is clinically suspected, biomarker testing provides a definitive diagnosis. 16

Interpretation of Amyloid and Tau Biomarkers

• Amyloid biomarkers:
  
  • Low cerebrospinal fluid (CSF) Aβ42 concentration indicates amyloid pathology. 16
  • Positive amyloid PET imaging confirms cerebral amyloid deposition. 16
• Tau/neurodegeneration biomarkers:
  
  • Elevated CSF total tau and phosphorylated tau concentrations support tau pathology. 16
• Critical interpretation rule: both amyloid and tau positivity must be demonstrated for an AD diagnosis; isolated amyloid positivity is non‑specific. 16
• Amyloid positivity may also be observed in cerebral amyloid angiopathy, Lewy body dementia, and age‑related amyloid accumulation without dementia, underscoring the need for concurrent tau assessment. 16

Atypical Presentations of Alzheimer’s Disease

• AD can present with language‑predominant (logopenic aphasia), visuospatial‑predominant (posterior cortical atrophy), or executive‑predominant variants, especially when onset occurs before age 65. 16

Common Diagnostic Pitfalls (Biomarker‑Related)

• Assuming that any memory impairment equals AD is erroneous; other dementias (FTD, Lewy body dementia, vascular dementia) may also feature memory complaints but with distinct patterns. 16
• Relying solely on amyloid biomarkers leads to misdiagnosis because amyloid positivity is not exclusive to AD; tau positivity must also be demonstrated. 16